Comparative Effectiveness of Autologous Hematopoietic Stem Cell Transplant vs Fingolimod, Natalizumab, and Ocrelizumab in Highly Active Relapsing-Remitting Multiple Sclerosis
Sign Up to like & getrecommendations! Published in 2023 at "JAMA Neurology"
DOI: 10.1001/jamaneurol.2023.1184
Abstract: Autologous hematopoietic stem cell transplant (AHSCT) is available for treatment of highly active multiple sclerosis (MS).To compare the effectiveness of AHSCT vs fingolimod, natalizumab, and ocrelizumab in relapsing-remitting MS by emulating pairwise trials.This comparative treatment… read more here.
Keywords: relapsing remitting; disability; effectiveness; fingolimod natalizumab ... See more keywords